Add-on-Statin Extended Release Nicotinic AcidLaropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure : An Open-Label Randomized Study

Abstract EN

Introduction.

Nicotinic acid (NA) and statins have been associated with reductions in blood pressure (BP).

Patients and Methods.

We recruited 68 normotensive and hypertensive dyslipidemic patients who were treated with a conventional statin dose and had not achieved lipid targets.

Patients were randomized to switch to high-dose rosuvastatin (40 mg/day) or to add-on current statin treatment with extended release (ER) NA/laropiprant (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks) for 3 months.

Results.

Switching to rosuvastatin 40 mg/day was not associated with significant BP alterations.

In contrast, the addition of ER-NA/laropiprant to current statin treatment resulted in a 7% reduction of systolic BP (from 134±12 to 125±10 mmHg, P<.001 versus baseline and P=.01 versus rosuvastatin group) and a 5% reduction of diastolic BP (from 81±9 to 77±6 mmHg, P=.009 versus baseline and P=.01 versus rosuvastatin group).

These reductions were significant only in the subgroup of hypertensives and were independent of the hypolipidemic effects of ER-NA/laropiprant.

Conclusions.

Contrary to the switch to high-dose rosuvastatin, the addition of ER-NA/laropiprant to statin treatment was associated with significant reductions in both systolic and diastolic BP.